Citalopram
- Generic Name
- Citalopram
- Brand Names
- Celexa, Ctp
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21FN2O
- CAS Number
- 59729-33-8
- Unique Ingredient Identifier
- 0DHU5B8D6V
- Background
Citalopram is an antidepressant belonging to the class of selective serotonin-reuptake inhibitors (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs. Citalopram enhances serotonergic transmission through the i...
- Indication
Citalopram is approved by the FDA for treating adults with major depressive disorder. It has also been used off-label to treat various diseases, including but not limited to sexual dysfunction, ethanol abuse, psychiatric conditions such as obsessive-compulsive disorder (OCD), social anxiety disorder, panic disorder, and diabetic neuropathy.
- Associated Conditions
- Alcohol Abuse, Anorexia Nervosa (AN), Binge Eating Disorder (BED), Bulimia Nervosa, Depression, Diabetic Neuropathies, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD), Separation Anxiety Disorder, Social Anxiety Disorder (SAD)
- Associated Therapies
- -
7T Amygdala and Citalopram Study
- Conditions
- Interventions
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 50
- Registration Number
- NCT06412315
Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions
- Conditions
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Food and Drug Administration (FDA)
- Target Recruit Count
- 240
- Registration Number
- NCT06192589
- Locations
- 🇺🇸
Spaulding Clinical Research, West Bend, Wisconsin, United States
DRACULA1 Partum Depression: an Integrated Molecular-pharmaco-imaging Study")
- First Posted Date
- 2023-11-14
- Last Posted Date
- 2023-11-14
- Target Recruit Count
- 15
- Registration Number
- NCT06131255
- Locations
- 🇮🇹
Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, MI, Italy
A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats
- Conditions
- Interventions
- Drug: FezolinetantDrug: ParoxetineDrug: GabapentinDrug: CitalopramDrug: ClonidineDrug: PregabalinDrug: EscitalopramDrug: DesvenlafaxineDrug: OxybutyninDrug: Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category aboveDrug: VenlafaxineDrug: Any other SSRI/SNRI not already specified
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 1000
- Registration Number
- NCT06049797
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸SUNY Downstate Health Sciences University, Brooklyn, New York, United States
🇺🇸Mohawk Valley Health System - Womens Health Center, Utica, New York, United States
Combined Antidepressant and Behavioural Intervention
- Conditions
- Interventions
- First Posted Date
- 2022-11-25
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 134
- Registration Number
- NCT05627154
- Locations
- 🇬🇧
Neurosciences Building, Warneford Hospital, Oxford, Oxfordshire, United Kingdom
Antidepressant Efficacy of Psychotherapy and Citalopram in Patients With Breast Cancer and Major Depression
- Conditions
- Interventions
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2022-07-05
- Lead Sponsor
- Hospital Universitari de Bellvitge
- Target Recruit Count
- 40
- Registration Number
- NCT05063604
- Locations
- 🇪🇸
Catalan Institute of Oncology, L'Hospitalet De Llobregat, Barcelona, Spain
SSRIs and TDCS Enhance Post-stroke Motor Recovery
- Conditions
- Interventions
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2021-09-13
- Lead Sponsor
- Chih-Wei Tang
- Target Recruit Count
- 80
- Registration Number
- NCT05041582
Safety of Liposom With Citalopram in Elderly Patients With Major Depressive Disorder
- Conditions
- Interventions
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Fidia Farmaceutici s.p.a.
- Target Recruit Count
- 150
- Registration Number
- NCT04975724
- Locations
- 🇮🇹
SOD Geriatria-UTIG Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy
🇮🇹Clinica Psichiatrica, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy
🇮🇹UOC Geriatria e Lungodegenza Geriatrica PO San Filippo e Nicola di Avezzano - ASL1 Avezzano Sulmona L'aquila, Avezzano, Italy
Post-stroke Depression Treatment Effect on Stroke Recurrence
- Conditions
- Interventions
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2021-03-01
- Lead Sponsor
- Ege University
- Target Recruit Count
- 1230
- Registration Number
- NCT04776226
- Locations
- 🇹🇷
Ege University, İzmir, Turkey
Improving Quality of Life in Early Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Western University, Canada
- Target Recruit Count
- 30
- Registration Number
- NCT04590612
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.